The therapeutic prospective of 5-MeO-copyright is hypothetical, but intriguing. Surveys of leisure customers propose swift anxiolytic and antidepressant properties not dissimilar to those getting probed in early-phase studies of psilocybin and LSD, as well as afterwards phase studies of ketamine and its analogues. 5-MeO-copyright shares comparable